PREPRINT NEW RESEARCH: The Impact of MFN on Oncology and Hematology Treatments
Preview
Vital Transformation is preparing a new analysis about the potential implications of Most Favored Nation (MFN) drug pricing policies for the U.S. oncology ecosystem, focusing on how international reference pricing could reshape provider economics, patient access, and innovation incentives. The analysis models the effect of benchmarking U.S. prices for cancer medicines against lower prices in selected peer countries and estimates substantial reimbursement reductions across multiple therapies.
While such policies are often framed as mechanisms to improve affordability, the analysis highlights the operational realities of oncology care delivery, where many treatments are purchased and administered by community providers under Medicare. Sharp declines in reimbursement would create situations where acquisition costs exceed payment, potentially forcing providers to alter treatment patterns, refer patients to hospital settings, or limit availability of new cancer medicines.
The research raises broader system-level questions about how pricing reforms interact with financial sustainability of oncology R&D, and the long-term incentives for biopharmaceutical innovation.
Read More
